Rockwell medical, inc. (RMTI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Net Sales

15,856

15,490

15,407

14,845

15,559

16,854

16,672

14,913

14,948

14,837

14,626

13,243

14,592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of Sales

14,743

14,378

15,423

14,112

14,549

15,670

14,703

18,930

15,669

-

13,555

11,744

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales

-

-

-

-

-

-

-

-

-

14,838

-

-

-

13,389

12,814

13,452

13,627

14,132

14,378

12,955

13,883

14,447

13,743

13,033

12,963

13,964

13,094

12,984

12,336

12,999

12,689

12,124

12,028

11,896

11,976

11,802

13,290

14,745

15,506

Cost of Sales

-

-

-

-

-

-

-

-

-

16,062

-

-

12,234

11,401

11,234

11,962

11,932

12,076

11,875

10,889

11,571

11,871

11,473

11,014

11,283

11,904

11,461

11,299

11,055

11,297

11,043

10,405

10,401

10,352

10,600

10,731

11,639

12,345

12,735

Gross Profit

1,112

1,111

-16

733

1,010

1,184

1,968

-4,017

-720

-1,224

1,071

1,498

2,357

1,988

1,579

1,489

1,694

2,056

2,503

2,065

2,312

2,576

2,269

2,018

1,679

2,059

1,633

1,685

1,280

1,702

1,645

1,718

1,626

1,544

1,376

1,071

1,651

2,400

2,771

Selling and Marketing

2,072

1,901

1,827

2,218

3,102

503

121

164

215

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and Administrative

5,273

4,657

4,623

5,496

6,220

7,397

6,037

5,526

3,116

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, General and Administrative

-

-

-

-

-

-

-

-

-

5,869

4,791

6,541

6,100

6,049

5,070

5,014

4,986

6,089

3,827

3,835

5,325

5,917

4,098

4,214

4,090

3,795

3,386

3,237

3,916

3,635

3,325

2,824

2,898

2,631

2,271

2,372

2,246

2,431

2,221

Litigation Settlement, Expense

-

-

-

430

-

-

-

1,030

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and Product Development

1,821

-

1,474

2,958

497

-

808

1,558

1,666

2,126

1,304

1,675

1,214

1,200

1,261

2,063

1,314

2,029

1,246

885

799

1,679

1,301

186

4,615

5,793

10,611

10,222

12,754

11,751

16,238

10,876

9,405

7,867

4,221

3,313

2,402

727

441

Operating Loss

-8,054

-7,402

-7,942

-10,370

-8,809

-9,424

-4,998

-12,296

-5,718

-9,221

-5,025

-6,718

-4,958

-5,262

-4,752

-5,588

-4,606

-6,063

-2,571

-2,654

-3,813

-5,020

-3,130

-2,382

-7,025

-7,529

-12,364

-11,775

-15,390

-13,684

-17,917

-11,981

-10,677

-8,955

-5,116

-4,615

-2,997

-759

109

Other Income (Expense)
Realized Gain on Investments

1

5

6

4

13

-0

-97

-122

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest Expense

101

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest Income

171

-

-

-

117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and Investment Income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

293

156

118

113

187

55

69

74

69

13

4

10

11

42

77

111

3

77

77

85

17

10

Interest Income

-

-

80

74

-

46

125

188

175

-

-

-

-

-

-

-

-

-

-

-

-

-1,549

-892

-858

-854

-872

-857

-92

-0

-0

-0

-0

-0

-0

-0

-0

-0

-1

-3

Other Income

-

-

-

-

-

-

-

-

-3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign Currency Gain

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Other Income

71

100

87

78

131

49

28

66

169

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income (Loss) Before Income Taxes

-

-

-

-

-

-

-

-

-

-9,039

-

-

-

-5,054

-4,563

-5,361

-4,419

-5,769

-2,414

-2,536

-3,699

-6,383

-3,967

-3,170

-7,805

-8,332

-13,208

-11,863

-15,379

-13,673

-17,875

-11,905

-10,566

-8,952

-5,039

-4,538

-2,912

-743

116

Income Tax Expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

404

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

-

-

-

0

Net Income (Loss) Attributable to Parent

-7,983

-7,302

-7,855

-10,292

-8,678

-9,375

-4,969

-12,230

-5,549

-9,039

-5,056

-7,082

-4,742

-5,054

-4,563

-5,361

-4,824

-5,769

-2,414

-2,536

-3,699

-6,383

-3,967

-3,170

-7,805

-8,332

-13,208

-11,863

-15,379

-13,673

-17,875

-11,905

-10,566

-8,952

-5,041

-4,538

-2,912

-743

116

Net Loss

-

-

-

-

-

-

-

-

-

181

-31

-364

216

207

188

227

186

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest

-

-

-

-

-

-

-

-

-

-9,039

-

-

-

-5,054

-4,563

-5,361

-4,419

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

116

Basic Earnings (Loss) per Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.04

0.01

Diluted Earnings (Loss) per Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.04

0.01

Basic and Diluted Net Loss per Share (in dollars per share)

-0.12

-0.11

-0.12

-0.18

-0.15

-0.16

-0.10

-0.24

-0.11

-0.18

-0.10

-0.14

-0.09

-

-

-

-

-0.12

-0.05

-0.05

-0.07

-0.14

-0.10

-0.08

-0.20

-0.21

-0.34

-0.38

-0.72

-0.66

-0.86

-0.58

-0.54

-0.49

-0.28

-0.26

-0.17

-

-

Basic and Diluted Weighted Average Shares Outstanding (in shares)

67,518

64,562

63,796

58,216

57,098

57,432

51,288

51,288

51,288

51,290

51,260

51,031

50,686

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-